Pancreas transplantation

Lessons learned from a decade of experience at wake forest Baptist medical center

Jeffrey Rogers, Alan C. Farney, Samer Al-Geizawi, Samy S. Iskandar, William Doares, Michael D. Gautreaux, Lois Hart, Scott Kaczmorski, Amber Reeves-Daniel, Stephanie Winfrey, Mythili Ghanta, Patricia L. Adams, Robert J. Stratta

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

This article reviews the outcome of pancreas transplantations in diabetic recipients according to risk factors, surgical techniques, and immunosuppression management that evolved over the course of a decade at Wake Forest Baptist Medical Center. A randomized trial of alemtuzumab versus rabbit anti-thymocyte globulin (rATG) induction in simultaneous kidney-pancreas transplantation (SKPT) at our institution demonstrated lower rates of acute rejection and infection in the alemtuzumab group. Consequently, alemtuzumab induction has been used exclusively in all pancreas transplantations since February 2009. Early steroid elimination has been feasible in the majority of patients. Extensive experience with surveillance pancreas biopsies in solitary pancreas transplantation (SPT) is described. Surveillance pancreas biopsy-directed immunosuppression has contributed to equivalent long-term pancreas graft survival rates in SKPT and SPT recipients at our center, in contrast to recent registry reports of persistently higher rates of immunologic pancreas graft loss in SPT. Furthermore, the impact of donor and recipient selection on outcomes is explored. Excellent results have been achieved with older (extended) donors and recipients, in recipients of organs from donation after cardiac death donors managed with extracorporeal support, and in African-American patients. Type 2 diabetics with detectable C-peptide levels have been transplanted successfully with outcomes comparable to those of insulinopenic diabetics. Our experiences are discussed in the light of findings reported in the literature.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalReview of Diabetic Studies
Volume8
Issue number1
DOIs
StatePublished - Nov 25 2011

Fingerprint

Pancreas Transplantation
Pancreas
Kidney Transplantation
Immunosuppression
Tissue Donors
Biopsy
Donor Selection
Tissue and Organ Procurement
Antilymphocyte Serum
C-Peptide
Graft Survival
Forests
African Americans
Registries
Survival Rate
Steroids
Rabbits
Transplants
Infection

Keywords

  • Alemtuzumab
  • Mycophenolate mofetil pancreas transplantation
  • Portal-enteric
  • Rabbit anti-thymocyte globulin
  • Simultaneous kidney-pancreas transplantation
  • Tacrolimus
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Internal Medicine
  • Medicine(all)

Cite this

Rogers, J., Farney, A. C., Al-Geizawi, S., Iskandar, S. S., Doares, W., Gautreaux, M. D., ... Stratta, R. J. (2011). Pancreas transplantation: Lessons learned from a decade of experience at wake forest Baptist medical center. Review of Diabetic Studies, 8(1), 17-27. https://doi.org/10.1900/RDS.2011.8.17

Pancreas transplantation : Lessons learned from a decade of experience at wake forest Baptist medical center. / Rogers, Jeffrey; Farney, Alan C.; Al-Geizawi, Samer; Iskandar, Samy S.; Doares, William; Gautreaux, Michael D.; Hart, Lois; Kaczmorski, Scott; Reeves-Daniel, Amber; Winfrey, Stephanie; Ghanta, Mythili; Adams, Patricia L.; Stratta, Robert J.

In: Review of Diabetic Studies, Vol. 8, No. 1, 25.11.2011, p. 17-27.

Research output: Contribution to journalReview article

Rogers, J, Farney, AC, Al-Geizawi, S, Iskandar, SS, Doares, W, Gautreaux, MD, Hart, L, Kaczmorski, S, Reeves-Daniel, A, Winfrey, S, Ghanta, M, Adams, PL & Stratta, RJ 2011, 'Pancreas transplantation: Lessons learned from a decade of experience at wake forest Baptist medical center', Review of Diabetic Studies, vol. 8, no. 1, pp. 17-27. https://doi.org/10.1900/RDS.2011.8.17
Rogers, Jeffrey ; Farney, Alan C. ; Al-Geizawi, Samer ; Iskandar, Samy S. ; Doares, William ; Gautreaux, Michael D. ; Hart, Lois ; Kaczmorski, Scott ; Reeves-Daniel, Amber ; Winfrey, Stephanie ; Ghanta, Mythili ; Adams, Patricia L. ; Stratta, Robert J. / Pancreas transplantation : Lessons learned from a decade of experience at wake forest Baptist medical center. In: Review of Diabetic Studies. 2011 ; Vol. 8, No. 1. pp. 17-27.
@article{a5d0837290c44fe3ae371b4329e6cc20,
title = "Pancreas transplantation: Lessons learned from a decade of experience at wake forest Baptist medical center",
abstract = "This article reviews the outcome of pancreas transplantations in diabetic recipients according to risk factors, surgical techniques, and immunosuppression management that evolved over the course of a decade at Wake Forest Baptist Medical Center. A randomized trial of alemtuzumab versus rabbit anti-thymocyte globulin (rATG) induction in simultaneous kidney-pancreas transplantation (SKPT) at our institution demonstrated lower rates of acute rejection and infection in the alemtuzumab group. Consequently, alemtuzumab induction has been used exclusively in all pancreas transplantations since February 2009. Early steroid elimination has been feasible in the majority of patients. Extensive experience with surveillance pancreas biopsies in solitary pancreas transplantation (SPT) is described. Surveillance pancreas biopsy-directed immunosuppression has contributed to equivalent long-term pancreas graft survival rates in SKPT and SPT recipients at our center, in contrast to recent registry reports of persistently higher rates of immunologic pancreas graft loss in SPT. Furthermore, the impact of donor and recipient selection on outcomes is explored. Excellent results have been achieved with older (extended) donors and recipients, in recipients of organs from donation after cardiac death donors managed with extracorporeal support, and in African-American patients. Type 2 diabetics with detectable C-peptide levels have been transplanted successfully with outcomes comparable to those of insulinopenic diabetics. Our experiences are discussed in the light of findings reported in the literature.",
keywords = "Alemtuzumab, Mycophenolate mofetil pancreas transplantation, Portal-enteric, Rabbit anti-thymocyte globulin, Simultaneous kidney-pancreas transplantation, Tacrolimus, Type 2 diabetes",
author = "Jeffrey Rogers and Farney, {Alan C.} and Samer Al-Geizawi and Iskandar, {Samy S.} and William Doares and Gautreaux, {Michael D.} and Lois Hart and Scott Kaczmorski and Amber Reeves-Daniel and Stephanie Winfrey and Mythili Ghanta and Adams, {Patricia L.} and Stratta, {Robert J.}",
year = "2011",
month = "11",
day = "25",
doi = "10.1900/RDS.2011.8.17",
language = "English (US)",
volume = "8",
pages = "17--27",
journal = "Review of Diabetic Studies",
issn = "1613-6071",
publisher = "Society for Biomedical Diabetes Research",
number = "1",

}

TY - JOUR

T1 - Pancreas transplantation

T2 - Lessons learned from a decade of experience at wake forest Baptist medical center

AU - Rogers, Jeffrey

AU - Farney, Alan C.

AU - Al-Geizawi, Samer

AU - Iskandar, Samy S.

AU - Doares, William

AU - Gautreaux, Michael D.

AU - Hart, Lois

AU - Kaczmorski, Scott

AU - Reeves-Daniel, Amber

AU - Winfrey, Stephanie

AU - Ghanta, Mythili

AU - Adams, Patricia L.

AU - Stratta, Robert J.

PY - 2011/11/25

Y1 - 2011/11/25

N2 - This article reviews the outcome of pancreas transplantations in diabetic recipients according to risk factors, surgical techniques, and immunosuppression management that evolved over the course of a decade at Wake Forest Baptist Medical Center. A randomized trial of alemtuzumab versus rabbit anti-thymocyte globulin (rATG) induction in simultaneous kidney-pancreas transplantation (SKPT) at our institution demonstrated lower rates of acute rejection and infection in the alemtuzumab group. Consequently, alemtuzumab induction has been used exclusively in all pancreas transplantations since February 2009. Early steroid elimination has been feasible in the majority of patients. Extensive experience with surveillance pancreas biopsies in solitary pancreas transplantation (SPT) is described. Surveillance pancreas biopsy-directed immunosuppression has contributed to equivalent long-term pancreas graft survival rates in SKPT and SPT recipients at our center, in contrast to recent registry reports of persistently higher rates of immunologic pancreas graft loss in SPT. Furthermore, the impact of donor and recipient selection on outcomes is explored. Excellent results have been achieved with older (extended) donors and recipients, in recipients of organs from donation after cardiac death donors managed with extracorporeal support, and in African-American patients. Type 2 diabetics with detectable C-peptide levels have been transplanted successfully with outcomes comparable to those of insulinopenic diabetics. Our experiences are discussed in the light of findings reported in the literature.

AB - This article reviews the outcome of pancreas transplantations in diabetic recipients according to risk factors, surgical techniques, and immunosuppression management that evolved over the course of a decade at Wake Forest Baptist Medical Center. A randomized trial of alemtuzumab versus rabbit anti-thymocyte globulin (rATG) induction in simultaneous kidney-pancreas transplantation (SKPT) at our institution demonstrated lower rates of acute rejection and infection in the alemtuzumab group. Consequently, alemtuzumab induction has been used exclusively in all pancreas transplantations since February 2009. Early steroid elimination has been feasible in the majority of patients. Extensive experience with surveillance pancreas biopsies in solitary pancreas transplantation (SPT) is described. Surveillance pancreas biopsy-directed immunosuppression has contributed to equivalent long-term pancreas graft survival rates in SKPT and SPT recipients at our center, in contrast to recent registry reports of persistently higher rates of immunologic pancreas graft loss in SPT. Furthermore, the impact of donor and recipient selection on outcomes is explored. Excellent results have been achieved with older (extended) donors and recipients, in recipients of organs from donation after cardiac death donors managed with extracorporeal support, and in African-American patients. Type 2 diabetics with detectable C-peptide levels have been transplanted successfully with outcomes comparable to those of insulinopenic diabetics. Our experiences are discussed in the light of findings reported in the literature.

KW - Alemtuzumab

KW - Mycophenolate mofetil pancreas transplantation

KW - Portal-enteric

KW - Rabbit anti-thymocyte globulin

KW - Simultaneous kidney-pancreas transplantation

KW - Tacrolimus

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=80055074989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055074989&partnerID=8YFLogxK

U2 - 10.1900/RDS.2011.8.17

DO - 10.1900/RDS.2011.8.17

M3 - Review article

VL - 8

SP - 17

EP - 27

JO - Review of Diabetic Studies

JF - Review of Diabetic Studies

SN - 1613-6071

IS - 1

ER -